ALHC · Alignment Healthcare, Inc.

Alignment Healthcare delivered a materially positive inflection in Q1 2026, transitioning from a $9.4 million net loss in Q1 2025 to $11.4 million net income — its first reported quarterly net profit. This turnaround was driven by disciplined top-line growth (33.3% YoY revenue increase to $1.235 billion), operational leverage (adjusted EBITDA up 87.6% YoY), and improved medical cost management (MBR improved 25 bps to 88.2%). Revenue growth outpaced membership growth (30.9% YoY), suggesting premium rate increases or favorable risk score adjustments. Management attributed the performance to execution across sales, clinical operations, and cost management — even while investing in people, processes, and AVA® technology. The company raised the midpoint of all full-year 2026 guidance metrics, signaling confidence in sustained momentum. Notably, the $128.7 million in operating cash flow — more than 11x net income — underscores strong underlying cash generation despite non-cash equity compensation and depreciation. The balance sheet remains robust, with $705.6 million in cash and equivalents and only $323.6 million in net long-term debt, providing strategic flexibility. Forward-looking statements emphasize continued focus on scaling the business and achieving 'embedded earnings potential,' though risks around MA funding, provider relationships, and regulatory approvals remain explicitly cited.